Medicare’s PET project
This article was originally published in The Gray Sheet
CMS seeks comments on alternatives to its "indication-by-indication" approach to determining whether positron emission tomography scans for cancer are reasonable and necessary. The Oct. 14 solicitation responds to extensive criticism by stakeholders. Despite an April 2004 deadline, CMS is still evaluating evidence for granting national coverage to brain, testicular, small-cell lung, cervical and pancreatic cancers (1"The Gray Sheet" Sept. 13, 2004, p. 4)...
You may also be interested in...
CMS' cautious approach to covering positron emission tomography indications has spurred criticism among the PET industry, which seeks to accelerate reimbursement to drive the technology's adoption
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.